Samsung Epis (A0126Z0) Q4 2025 earnings summary

Executive summary

• Q4 2025 consolidated revenue was 252B KRW with an operating loss of 64B KRW, reflecting only two months of operation post spin-off.

• Bioepis segment reported Q4 2025 revenue of 429B KRW and operating profit of 29B KRW, up 23% and 14% YoY, respectively.

• FY 2025 Bioepis revenue reached 1,672B KRW with operating profit of 376B KRW, up 28% and 101% YoY, excluding milestones.

Financial highlights

• Q4 2025 Bioepis product sales were 425B KRW, operating profit 25B KRW.

• FY 2025 Bioepis product sales totaled 1,627B KRW, operating profit 331B KRW.

• Holdings' two-month revenue was 252B KRW, with losses due to R&D, provisioning, and non-cash adjustments.

• Net profit for Bioepis in Q4 2025 was 211B KRW, up 193% YoY.

Outlook and guidance

• Targeting over 10% growth in product sales for 2026, driven by ramp-up of early-stage launches and new products.

• Plan to advance at least one novel drug candidate into IND submission annually.